BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas

Low-grade gliomas (LGG) are the most common central nervous system tumors in children. Prognosis depends on complete surgical resection. For patients not amenable of gross total resection (GTR) new approaches are needed. The BRAF mutation V600E is critical for the pathogenesis of pediatric gliomas a...

Full description

Bibliographic Details
Main Authors: Francesca Del Bufalo, Giulia Ceglie, Antonella Cacchione, Iside Alessi, Giovanna Stefania Colafati, Andrea Carai, Francesca Diomedi-Camassei, Emmanuel De Billy, Emanuele Agolini, Angela Mastronuzzi, Franco Locatelli
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-11-01
Series:Frontiers in Oncology
Subjects:
pediatric central nervous system tumors
low-grade gliomas
vemurafenib
targeted therapies
pediatric neuro-oncology
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2018.00526/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2018.00526/full

Similar Items